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Use of the first-person pronoun in schizophrenia
In their recent publication, Fineberg et al examined word use in
first-person accounts of schizophrenia in comparison with word
use in first-person accounts of mood and anxiety disorders.1
One of their hypotheses concerned the use of the first-person
singular pronoun ‘I’. On the basis of research showing patients
with mood disorders to be particularly self-focused, as well as
phenomenological reports by patients suffering from schizophrenia
describing a disrupted sense of self, they predicted that ‘writers with
schizophrenia would use ‘‘I’’ less often than persons with mood
disorder’. They found this hypothesis to be supported by their data.
One obvious limitation of this study, admitted by the authors, is
the lack of a healthy control group. Data from two such control
groups, however, are readily at hand. First, one can compare the word
frequencies found in their first-person accounts with their frequency
in general language, as represented in reference corpora such as the
Corpus of Contemporary American English.2 Second, in order to
compare a text format that is as similar as possible to first-person
accounts of mental illness, one can make use of articles published in
the Schizophrenia Bulletin under the rubric ‘First-person account’ that
are not written by sufferers of schizophrenia, but by (supposedly)
healthy family and friends of someone with schizophrenia (I will refer
to those as ‘second- person’ accounts). Such comparison, based on
analyses of a corpusof the SchizophreniaBulletinusingCQPsoftware,3
yields results that markedly differ from Fineberg et al’s findings (for a
general introduction to corpus linguistics, see Lu¨deling & Kyto¨4).
Since 1979, the Schizophrenia Bulletin has published 98 first-
person accounts and 30 second-person accounts of schizophrenia.
The frequency of ‘I’ in the first-person accounts is 34 621.67/106
words and 20 804.18/106 words in the second-person accounts.
The authors of the first-person accounts use ‘I’ 3.34 times more
often than it is used in general American English and 1.90 times
more often than it occurs in general spoken American English.
Comparing first- and second-person accounts, ‘I’ is used 1.66
times more often by people identifying as having schizophrenia
spectrum disorders than by their mentally healthy friends and
family members. The log likelihood test shows this difference to
be significant (P50.01).
Authors identifying as having schizophrenia thus use the first-
person singular pronoun more often than healthy controls.
Therefore, Fineberg et al’s finding that authors with schizophrenia
use ‘I’ less often than authors with mood disorders does not
warrant any inferences regarding pathologies of the self in
schizophrenia. To further investigate the relationship between
language and self-disturbances, it would be desirable to analyse
linguistic data from people undergoing an acute psychotic episode
as well as to consider pronouns in their wider grammatical context
rather than looking at mere word frequencies.
1 Fineberg SK, Deutsch-Link S, Ichinose M, McGuiness T, Bessette AJ,
Chung CK, et al. Word use in first-person accounts of schizophrenia.
Br J Psychiatry 2014; doi: 10.1192/bjp.bp.113.140046.
2 Brigham Young University. The Corpus of Contemporary American English.
Brigham Young University (http://corpus2.byu.edu/coca).
3 Hardie A. CQPweb – combining power, flexibility and usability in a corpus
analysis tool. Int J Corpus Linguist 2012; 17: 380–409.
4 Lu¨deling A, Kyto¨ M. Corpus Linguistics – An International Handbook.
De Gruyter, 2009.
Anke Maatz, speciality trainee in psychiatry and postdoctoral research fellow,
University Hospital of Psychiatry Zurich, Switzerland. Email: anke.maatz@puk.zh.ch
doi: 10.1192/bjp.205.5.409
Authors’ reply: We very much appreciate the concerns Dr
Maatz raises. Indeed, we raised many of them in our discussion.
Here we’ll take the opportunity to elaborate on our decision-
making process with regard to the analyses we reported.
As Dr Maatz and we ourselves point out, we did not include
a non-psychiatric control group in our analysis. We found it
difficult to identify an appropriate control for our particular
corpus. Writing about illness in a journal for medical professionals
is a rather particular kind of enterprise that commands specific
language. We considered the caregiver and family-member
accounts in the Schizophrenia Bulletin (which Dr Maatz called
‘second-person accounts’). However, we were concerned about
comparing samples with different themes (writing about oneself
in the first group, writing about other people in the proposed
control group). That would almost certainly change pronoun
use. Furthermore, family members can sometimes present with
attenuated, subclinical versions of the experiences, behaviours
and deficits observed in psychotic illness.2 We thought these might
detract from our original objective, which was to analyse word use
by people with schizophrenia compared with that by individuals
with another mental illness.
We agree with Dr Maatz that this comparison between two
illness groups limits the conclusions we can draw. We felt we were
suitably circumspect but we are happy to rehearse the point. We
are gathering new data, in which process we ask standard
questions of participants (including questions that engage
discussion of self, others, and impersonal topics). Furthermore
we are gathering those data from participants at various illness
phases (prodrome, acute psychosis, chronic illness) in order to
examine the hypotheses suggested by our initial study of the
Schizophrenia Bulletin corpus.
With respect to context analysis (how words co-occur), we
agree that this is an interesting and important issue. We do not
think that our word-counting approach is the final word on
meaning in computational linguistics (no pun intended). We are
eager to analyse larger meaning structures in our corpus using
the new computational techniques Dr Maatz suggests,3 among
others.4 We look forward to reading more about the analyses of
the Schizophrenia Bulletin corpus she mentions in the peer-reviewed
literature.
Indeed, we hope that this approach, analysing the writing and
speech of patients with mental illness using computational
linguistics, becomes another tool employed by those committed
to understanding and treating mental illness. We are glad that
Dr Maatz is interested in joining us in this venture.
1 Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, et al.
Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively
intact siblings of patients with schizophrenia. Am J Psychiatry 2003; 160:
709–19.
2 Hardie A. CQPweb – combining power, flexibility and usability in a corpus
analysis tool. Int J Corpus Linguistics 2012; 17: 380–409.
3 Brown C, Snodgrass T, Kemper SJ, Herman R, Covington MA. Automatic
measurement of propositional idea density from part-of-speech tagging.
Behav Res Methods 2008; 40: 540–5.
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BDNF and proBDNF as biomarkers for bipolar disorder
I read with great interest the recent article by Li et al, describing
plasma levels of brain-derived neurotrophic factor (BDNF) in
patients with bipolar disorder in their first depressive episode.1
A total of 203 patients with a first major depressive episode, as well
as 167 healthy controls, were enrolled. After 3 years of bi-annual
follow-up, 164 patients with a major depressive episode
completed, and of these, 21 patients were diagnosed as having
bipolar disorder and 143 patients were diagnosed as having major
depressive disorder. At baseline, patients with bipolar disorder and
depression showed significantly lower BDNF mRNA levels
(P50.001 and P=0.02, respectively) and plasma BDNF levels
(P= 0.002 and P=0.01, respectively) compared with healthy
controls. Interestingly, plasma BDNF levels in patients with bipolar
disorder were lower than those in patients with depression.
This study suggests that the model for predicting bipolar
disorder during a first depressive episode is a combination of
BDNF mRNA with plasma BDNF levels.1 BDNF (mature BDNF)
is a 13 kDa polypeptide, which is initially synthesised as a
precursor protein, preproBDNF, in the endoplasmic reticulum.
Following cleavage of the signal peptide, proBDNF (~32 kDa) is
converted to mature BDNF by extracellular proteases. It was
initially thought that only secreted, mature BDNF was biologically
active, and that proBDNF, localised intracellularly, served as an
inactive precursor. However, accumulating evidence shows that
both proBDNF and mature BDNF are active, eliciting opposing
effects via the p75NTR and TrkB receptors, respectively, and that
both forms play important roles in several physiological
functions.2
The enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems) used by Li et al recognise both proBDNF (precursor of
BDNF) and mature BDNF, because of the limited specificity of
the BDNF antibody.3 Using newly available human proBDNF
and mature BDNF ELISA kits, which differentiate between the
BDNF forms, we have reported high levels of both proBDNF
and mature BDNF in human serum.3 We reported that serum
levels of mature BDNF, but not proBDNF, in patients with major
depressive disorder were significantly lower than those in healthy
controls.4 And we recently found that serum levels of mature
BDNF and the ratio of mature BDNF to proBDNF in mood-
stabilised patients with bipolar disorder were significantly higher
than in healthy controls.4 Interestingly, serum levels of proBDNF
in mood-stabilised patients with bipolar disorder were
significantly lower than those in healthy controls.5 These findings
were confirmed in two independent cohorts (Sahlgrenska set and
Karolinska set in Sweden).5 Considering the high levels of both
proBDNF and mature BDNF in human serum, and their putative
opposing functions, it would be clinically and scientifically inter-
esting to measure the individual serum levels of proBDNF and
mature BDNF in this cohort study.
1 Li Z, Zhang C, Fan J, Yuan C, Huang J, Chen J, et al. Brain-derived
neurotrophic factor levels and bipolar disorder in patients in their first
depressive episode: 3-year prospective longitudinal study. Br J Psychiatry
2014; 205: 29–35.
2 Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood
disorders: an historical overview and future directions. Psychiatry Clin
Neurosci 2010; 64: 341–57.
3 Yoshida T, Ishikawa M, Iyo M, Hashimoto K. Serum levels of mature brain-
derived neurotrophic factor and its precursor proBDNF in healthy subjects.
Open Clin Chem J 2012; 5: 7–12.
4 Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al.
Decreased serum levels of mature brain-derived neurotrophic factor (BDNF),
but not its precursor proBDNF, in patients with major depressive disorder.
PLoS One 2012; 7: e42676.
5 So¨dersten K, PI´lsson E, Ishima T, Funa K, Lande´n M, Hashimoto K, et al.
Abnormality in serum levels of mature brain-derived neurotrophic factor
(BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar
disorder: a study of two independent cohorts. J Affect Dis 2014; 160: 1–9.
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Authors’ reply: While we agree with Professor Hashimoto’s
comments regarding the predictive role of mature brain-derived
neurotrophic factor (mBDNF) and its precursor, proBDNF, in
bipolar disorder, several points merit further discussion.
First, we presented preliminary data describing a potential role
for BDNF as a biomarker for predicting bipolar disorder in major
depressive disorder, although we detected the serum BDNF level
using commercial kits that do not differentiate between mBDNF
and proBDNF. When we reviewed the literature regarding
mBDNF and proBDNF in bipolar disorder and major depressive
disorder, we noticed that lower serum levels of mBDNF and
higher serum levels of proBDNF were found among patients with
major depressive disorder.1,2 So¨dersten et al also reported that
higher serum levels of mBDNF and lower proBDNF were observed
among patients with bipolar disorder.3 These disparate results
suggest that levels of mBDNF and proBDNF, as well as the ratio
of mBDNF to proBDNF, might be sensitive enough to help
differentiate bipolar disorder from major depressive disorder.
Second, our previous studies indicated that BDNF probably
has some sex-specific characteristics. Tang et al4 reported that
the ratio of mBDNF to proBDNF differs in a sex-specific manner
in zebra finches. These findings suggest that mBDNF and
proBDNF are different in males and females and should be further
investigated.
Third, the findings of one of our previous studies implied that
genetic interactions between genes encoding BDNF and its
receptor enhance the risk of treatment-resistant depression.5
Recent studies have found that mBDNF and proBDNF elicit
biological effects via interaction with their respective receptors,
p75NTR and TrkB. Accordingly, we concluded that evaluations
of mBDNF and proBDNF should also consider their receptors.
On the whole, we appreciate Professor Hashimoto’s insightful
comments in directing our future work.
1 Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al.
Decreased serum levels of mature brain-derived neurotrophic factor (BDNF),
but not its precursor proBDNF, in patients with major depressive disorder.
Plos One 2012; 7: e42676.
2 Zhou L, Xiong J, Lim Y, Ruan Y, Huang C, Zhu Y, et al. Upregulation of blood
proBDNF and its receptors in major depression. J Affect Disord 2013; 150:
776–84.
3 So¨dersten K, Palsson E, Ishima T, Funa K, Landen M, Hashimoto K, et al.
Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF)
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and its precursor proBDNF in mood-stabilized patients with bipolar disorder:
A study of two independent cohorts. J Affect Disorders 2014; 160: 1–9.
4 Tang YP, Wade J. Developmental changes in BDNF protein in the song
control nuclei of zebra finches. Neuroscience 2013; 250: 578–87.
5 Li Z, Zhang Y, Wang Z, Chen J, Fan J, Guan Y, et al. The role of BDNF, NTRK2
gene and their interaction in development of treatment-resistant depression:
Data from multicenter, prospective, longitudinal clinic practice. J Psychiatr
Res 2013; 47: 8–14.
Chen Zhang, MD, PhD, Zezhi Li, MD, PhD, Yiru Fang, MD, PhD, Professor, Division
of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University
School of Medicine, Shanghai, China. Email: yirufang@gmail.com
doi: 10.1192/bjp.205.5.410a
Early and delayed treatment of bipolar disorder
Using Danish registry data, Kessing et al examined the relationship
between lithium response and the timing of treatment (early v.
delayed).1 Early treatment was associated with an increased
probability of lithium response. This is a clinically important
finding, given the increasing emphasis on early intervention in
bipolar disorder. The results of the Kessing et al study are
sobering. Only few patients, particularly among those for whom
treatment was delayed, responded to lithium. Several factors
may have contributed to the reported results.
The study did not – and possibly could not – control for the
cycle shortening that is observed after successive episodes of
bipolar disorder. Although the interpretation of such cycle
shortening has been debated,2 it is well established that early cycles
are significantly longer than those occurring later; consequently,
early in the course of illness one would expect longer spontaneous
remissions regardless of treatment. This effect may be partially
responsible for the greater treatment response in patients receiving
early intervention in the Kessing et al study.
Naturalistic studies typically demonstrate full response in
about 30% of participants3 (that is, no recurrences, or the Kessing
et al criterion, in treatment-adherent patients), which is markedly
greater than the response rate observed by Kessing et al. This
discrepancy could be related to age at first contact. The average
age of participants whom Kessing et al reported as having received
early and late treatment was 46.7 years and 49.1 years, respectively.
The natural history of bipolar disorder includes an average age at
onset in the second or third decade of life. The trajectory of the
illness, where mania typically develops as the last stage, delays
the diagnosis of bipolar disorder. Also, there is often a substantial
delay in starting treatment even following the diagnosis of bipolar
disorder.4,5 These reports, in conjunction with the advanced age at
index presentation, and high rates of antidepressant, antipsychotic
and anticonvulsant use in the Kessing et al study suggest that
participants may have been afflicted with bipolar disorder for
some time before ‘first contact’. In a sample of 450 participants,
Baldessarini et al reported a negative relationship between
treatment latency and effect of treatment on time spent ill.5 If
the aforementioned findings are generalisable to the Danish
sample, the reduced overall treatment responses may be
interpreted as a consequence of relatively advanced participant age.
Finally, Kessing et al analysed data collected since 1995. Is it
possible that participants had received lithium during the years
prior? This would further complicate the interpretations of sample
responsiveness to lithium, regardless of early or late initiation. In
conclusion, we suggest that the findings presented by Kessing et al
are limited by the lack of control for inter-participant differences
in the manifestation of the natural history of bipolar disorder. Such
control may be difficult, or in some cases impossible, to achieve
using registry-based observational data, but is nevertheless
imperative to understanding the effects of early v. late treatment
prophylaxis in relapsing–remitting illnesses such as bipolar disorder.
1 Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in
bipolar disorder. Br J Psychiatry 2014; 205: 214–20.
2 Oepen G, Baldessarini RJ, Salvatore P, Slater E. On the periodicity of manic-
depressive insanity, by Eliot Slater (1938): translated excerpts and
commentary. J Affect Disord 2004; 78: 1–9.
3 Garnham J, Munro A, Slaney C, MacDougall M, Passmore M, Duffy A, et al.
Prophylactic treatment response in bipolar disorder: Results of a naturalistic
observation study. J Affect Disord 2007; 104: 185–90.
4 Ortiz A, Bradler K, Slaney C, Garnham J, Ruzickova M, O’Donovan C, et al.
An admixture analysis of the age at index episodes in bipolar disorder.
Psychiatr Res 2011; 188: 34–9.
5 Baldessarini RJ, Tondo L, Hennen J. Treatment-latency and previous episodes:
relationships to pretreatment morbidity and response to maintenance
treatment in bipolar I and II disorders. Bipolar Disord 2003; 5: 169–79.
Abraham Nunes, MD, MBA, Tomas Hajek, MD, PhD, Martin Alda, MD,
Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Email: malda@dal.ca
doi: 10.1192/bjp.205.5.411
Authors’ reply: We are confident that the relatively low
response rates to lithium in our study relate to the narrow
definition of lithium response, rather than to characteristics of
the included patients.1 Thus, we intended to characterise patients
who had an excellent response to lithium monotherapy; that is,
patients who were ‘cured’ from further affective episodes following
a start-up period of lithium as in a prior study.2 We used two
robust clinical indicators to define excellent lithium response:
(a) lithium prescribed in monotherapy; and (b) no need for
psychiatric hospital admission. By doing this, we defined lithium
response in a rather rigorous way, resulting in relatively low rates
of response. We do not find that our definition of lithium
response hampered the finding of the study that early treatment
with lithium was associated with increased probability of excellent
lithium response compared with delayed treatment, or hampered
the generalisability of this finding. Although cycle acceleration
occurs on average in bipolar disorder3,4 the results of our study
may suggest that early treatment with lithium might prevent
progression of bipolar disorder.
1 Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in
bipolar disorder. Br J Psychiatry 2014; 205: 214–20.
2 Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response
to lithium: results from a nationwide register-based study. Int Clin
Psychopharmacol 2011; 26: 323–8.
3 Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and
bipolar disorders. Naturalistic study, 1994–1999. Br J Psychiatry 2004; 185:
372–7.
4 Kessing LV, Olsen EW, Andersen PK. Recurrence in affective disorder:
analyses with frailty models. Am J Epidemiol 1999; 149: 404–11.
Lars Vedel Kessing, Psychiatric Center Copenhagen, Department O and Faculty
of Health and Medical Sciences, University of Copenhagen, Per Kragh Andersen,
Department of Biostatistics, University of Copenhagen, Denmark. Email:
Lars.Vedel.Kessing@regionh.dk
doi: 10.1192/bjp.205.5.411a
‘Reasonable adjustments’ for vulnerable patients
We support the views of Tuffrey-Wijne & Hollins1 and their
argument for the NHS to take an organisational approach to
embed documentation and provision of reasonable adjustments
for those with protected characteristics under the Equalities Act
2010. Lord Darzi defined quality for the NHS as comprising three
dimensions: safety, effectiveness and patient experience.2 The
provision of reasonable adjustments is central to each of these.
Safety – Tuffrey Wijne & Hollins rightly identify the lack of
provision of reasonable adjustments as being a patient safety issue.
The Confidential Inquiry into Premature Deaths of People with
411
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Learning Disabilities (CIPOLD)3 demonstrated an underlying
culture in which people with intellectual disabilities were
disadvantaged in accessing equitable healthcare and at risk of
premature death because equality for disabled people was assumed
to mean treating them the same as others. It does not. Alternative
methods of making services available have to be found in order
to achieve equality of outcomes. Mizen et al, for example,
demonstrated that clinical guidelines can actually increase health
inequalities for people with intellectual disabilities if reasonable
adjustments are not made.4 If the lack of reasonable adjustments
threatens to compromise safety as, in very many cases, it does
for people with intellectual disabilities, this needs to be reported
and reviewed as a patient safety issue.
Effectiveness – evidence put forward by Tuffrey-Wijne et al
suggests that ward culture, staff attitudes and staff knowledge
are crucial in ensuring that hospital services are accessible to
vulnerable patients.5 Effective care is that which is tailored to
the needs of the patient, and this must involve an understanding
of the adjustments they need in order to be able to receive
appropriate medical and nursing care. In our view, we should
go further than Tuffrey-Wijne & Hollins’ requirement for Care
Quality Commission inspections in England and Wales to oversee
patient-specific recording of reasonable adjustments. We also need
to be confident that such adjustments are being delivered, and for
evidence to be provided of adequate arrangements being in place.
Patient experience – Turner & Robinson note that it is difficult
for people with intellectual disabilities and their families to
influence policy and practice in healthcare systems if they are
not visible within them and if involvement mechanisms such as
surveys and focus groups are not accessible to them.6 Both the
Death by Indifference7 and CIPOLD reports highlighted the lack
of attention paid to the views of patients and their families,
preventing them from becoming active partners in their care;
the CIPOLD report additionally noted the devastating impact
on future care that a poor experience of healthcare can have for
some people with intellectual disabilities. The provision of
reasonable adjustments needs to extend to the ways in which
we garner the views of people with intellectual disabilities,
communicate with them, and place them at the centre of their care.
The CIPOLD report made 18 recommendations, which
included (a) clear identification of people with intellectual
disabilities on the NHS central registration system and in all
health care records, and (b) reasonable adjustments required by,
and provided to, individuals, to be audited annually and examples
of best practice shared across agencies and organisations.3
It is now 4 years since the Equalities Act 2010 came into force.
Our adherence to the Act must be sharpened in the light of the
health inequalities faced by people with protected characteristics,
including those with intellectual disabilities, so clearly
demonstrated in successive reports. We all have a responsibility,
and we all have a role to play, in ensuring equal outcomes for
vulnerable people through the provision of reasonable
adjustments, but strong leadership is central to making it happen.
1 Tuffrey-Wijne I, Hollins, S. Preventing ‘deaths by indifference’: identification
of reasonable adjustments is key. Br J Psychiatry 2014; 205: 86–7.
2 Department of Health. High Quality Care for All: NHS Next Stage Review Final
Report. Department of Health, 2008.
3 Heslop P, Blair P, Fleming P, Hoghton M, Marriott A, Russ L. The confidential
inquiry into premature deaths of people with intellectual disabilities in the
UK: a population-based study. Lancet 2014; 383: 889–95.
4 Mizen L, Macfie M, Findlay L, Cooper S, Melviille C. Clinical guidelines
contribute to the health inequities experienced by individuals with
intellectual disabilities. Implement Sci 2012; 7: 42.
5 Tuffrey-Wijne I, Goulding L, Giatras N, Abraham E, Gillard S, White S, et al.
The barriers to and enablers of providing reasonably adjusted health services
to people with intellectual disabilities in acute hospitals: evidence from a
mixed-methods study. BMJ Open 2014; 4: e004606.
6 Turner S, Robinson C. Reasonable Adjustments for People with Learning
Disabilities – Implications and Actions for Commissioners and Providers of
Healthcare. Improving Health and Lives: Learning Disabilities Observatory,
2011.
7 Mencap. Death by Indifference. Mencap, 2007.
Pauline Heslop, Reader in Intellectual Disabilities Research, Matthew Hoghton,
Anna Marriott, University of Bristol. Email: pauline.heslop@bristol.ac.uk
doi: 10.1192/bjp.205.5.411b
Authors’ reply: We welcome the detailed response from Heslop
et al giving more evidence in support of our recommendation for
the effective use of reasonable adjustments during in-patient care.
They also draw attention to the need for these to be properly
audited by staff who understand the Equality Act 2010, which in
our view would require an extensive educational programme, as
there is no evidence that current audits are much more than a
box-ticking exercise.
They repeat an earlier and often made recommendation that
people with intellectual disabilities should be identified on a
national NHS database. NHS England has already decided to set
up a national learning-disability mortality review function, which
will require a national database. Regrettably, this cannot
commence until data linkages have been enabled by the NHS
and the Health and Social Care Information Centre and it seems
unlikely that this will be achieved until next summer.1 Strong
advocacy is needed to ensure there are no further delays in giving
priority to this work.
1 Hansard. HL Deb 30 July 2014 vol 755 col 1583.
Sheila Hollins, St George’s University of London, Irene Tuffrey-Wijne, PhD,
Kingston University and Faculty of Health, Social Care and Education, St George’s
University of London. Email: hollinss@parliament.uk
doi: 10.1192/bjp.205.5.412
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Corrections
Aripiprazole once-monthly for treatment of schizophrenia: double-
blind, randomised, non-inferiority study. BJPsych, 205, 135–144.
Figure 3(a), p. 141: x-axis label should be ‘Days from randomisation’.
The online version of this paper has been corrected post-publication,
in deviation from print and in accordance with this correction.
Cost-effectiveness of injectable opioid treatment v. oral methadone
for chronic heroin addiction. BJPsych, 203, 341–349. In the abstract,
the second sentence of the Results should read: ‘Costs overall were
highest for oral methadone (mean £15 805 v. £13 410 injectable
heroin and £10 945 injectable methadone; P=n.s.) due to higher
costs of criminal activity’. These data were reported correctly in
the body of the paper (Table 2, p. 344). The online version of this
paper has been corrected post-publication, in deviation from
print and in accordance with this correction.
doi: 10.1192/bjp.205.5.412a
10.1192/bjp.205.5.409Access the most recent version at DOI: 
2014, 205:409.BJP 
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